Applied Genetic Technologies (AGTC) Stock Rating Reaffirmed by Cantor Fitzgerald

Applied Genetic Technologies (NASDAQ:AGTC)‘s stock had its “hold” rating reissued by Cantor Fitzgerald in a report issued on Wednesday. They currently have a $9.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 127.85% from the stock’s current price.

AGTC has been the topic of a number of other research reports. ValuEngine lowered shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research lowered shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $10.17.

Shares of Applied Genetic Technologies (NASDAQ AGTC) traded down $0.05 during trading hours on Wednesday, hitting $3.95. 65,700 shares of the stock were exchanged, compared to its average volume of 112,573. The firm has a market capitalization of $72.37, a price-to-earnings ratio of -19.75 and a beta of 1.62. Applied Genetic Technologies has a 52 week low of $3.25 and a 52 week high of $9.45.

Applied Genetic Technologies (NASDAQ:AGTC) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Applied Genetic Technologies had a negative net margin of 8.78% and a negative return on equity of 2.86%. equities research analysts anticipate that Applied Genetic Technologies will post -1.14 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in AGTC. Ativo Capital Management LLC acquired a new position in Applied Genetic Technologies in the second quarter valued at $439,000. Virtu KCG Holdings LLC acquired a new position in Applied Genetic Technologies in the second quarter valued at $178,000. Dimensional Fund Advisors LP lifted its holdings in Applied Genetic Technologies by 66.6% in the second quarter. Dimensional Fund Advisors LP now owns 266,441 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 106,558 shares during the period. Numeric Investors LLC lifted its holdings in Applied Genetic Technologies by 23.6% in the second quarter. Numeric Investors LLC now owns 780,088 shares of the biotechnology company’s stock valued at $3,978,000 after buying an additional 148,799 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Applied Genetic Technologies by 1,080.3% in the second quarter. Goldman Sachs Group Inc. now owns 143,606 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 131,439 shares during the period. Institutional investors and hedge funds own 46.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/18/applied-genetic-technologies-agtc-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply